This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
STXS Secures FDA Approval for GenesisX to Broaden Surgical Robotics
by Zacks Equity Research
Stereotaxis wins FDA clearance for GenesisX, a streamlined robotic system aimed at boosting hospital adoption and accelerating growth.
BSXNegative Net Change STXSPositive Net Change HQYNo Net Change SOLVPositive Net Change
medical medical-devices
Is Force Feedback the Next Big Catalyst for ISRG's da Vinci Sales?
by Indrajit Bandyopadhyay
Intuitive Surgical's new force-feedback upgrades for da Vinci 5 could spark its next adoption wave as early clinical evidence strengthens.
SYKPositive Net Change ISRGPositive Net Change GMEDPositive Net Change
medical medical-devices
Hologic Expands European Reach of Genius Digital Diagnostics System
by Moumi Mondal
HOLX gains expanded CE marking for its Genius Digital Diagnostics System, enabling imaging of both cell and tissue specimens on one platform.
TMOPositive Net Change HOLXPositive Net Change QGENPositive Net Change
medical medical-devices
Insulet Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand
by Zacks Equity Research
PODD's Q3 earnings and revenues top forecasts, with strong Omnipod growth and margin expansion lifting shares.
BSXNegative Net Change ISRGPositive Net Change PODDNegative Net Change MEDPPositive Net Change
earnings medical medical-devices
Alto Ingredients (ALTO) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
ALTONo Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
MDT Q2 Earnings Preview: Cardiovascular Unit Likely to Boost Growth
by Zacks Equity Research
Medtronic's Q2 results may see a lift from solid Cardiovascular momentum and strong Diabetes segment growth.
MDTPositive Net Change VEEVPositive Net Change ASNDPositive Net Change ACOGPositive Net Change
earnings medical medical-devices
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now
by Zacks Equity Research
DXCM's strong Q3 growth, expanding CGM coverage and innovation-driven momentum position it for sustained adoption despite rising competition.
BSXNegative Net Change DXCMPositive Net Change HQYNo Net Change SOLVPositive Net Change
medical medical-devices
Hims & Hers Scales Technology-Enabled, Vertically Integrated Care
by Debanjana Dey
HIMS deepens its technology-enabled care model with new offerings in GLP-1 weight loss, hormone health, and custom treatments.
TDOCPositive Net Change AMWLNegative Net Change HIMSPositive Net Change
medical medical-devices
Penumbra Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand
by Zacks Equity Research
PEN's Q3 results impress with double-digit sales growth, margin expansion and a strong 20% stock surge after its earnings beat.
BSXNegative Net Change ISRGPositive Net Change PENPositive Net Change MEDPPositive Net Change
earnings medical medical-devices
CVS Health Lifts Adjusted EPS Outlook: What's Driving It?
by Moumi Mondal
CVS raises its full-year EPS outlook after a strong quarter, driven by gains across all segments and solid pharmacy growth.
AMZNPositive Net Change CVSNegative Net Change ELVNegative Net Change
medical medical-devices
Do Options Traders Know Something About Penumbra Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to PEN stock based on the movements in the options market lately
PENPositive Net Change
medical-devices
Kennametal (KMT) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
KMTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Implied Volatility Surging for Thermo Fisher Stock Options
by Zacks Equity Research
Investors need to pay close attention to TMO stock based on the movements in the options market lately.
TMOPositive Net Change
medical medical-devices
What's Behind Boston Scientific's Optimism for Urology Growth?
by Moumi Mondal
BSX sees stronger 2026 prospects for Urology, powered by Axonics integration, innovation and global Stone Management momentum.
BSXNegative Net Change ISRGPositive Net Change ALGNNegative Net Change
medical medical-devices
ISRG Stock Gains More than 28% in a Month: Should You Buy, Hold or Sell?
by Indrajit Bandyopadhyay
Intuitive Surgical's shares soar over 28% in a month on da Vinci 5 momentum, but margin and valuation pressures suggest caution for new buyers.
MDTPositive Net Change SYKPositive Net Change ISRGPositive Net Change
medical medical-devices
AMN Stock Gains Following Q3 Earnings & Revenue Beat, Margins Down
by Zacks Equity Research
AMN Healthcare beats third-quarter 2025 earnings and revenue estimates despite lower margins and year-over-year declines across key segments.
BSXNegative Net Change AMNNegative Net Change WSTPositive Net Change EXASPositive Net Change
earnings medical medical-devices
Hims & Hers Expands AI-Driven Personalized and Subscription-Based Care
by Debanjana Dey
HIMS expands its AI-powered, subscription-based care model globally, backed by $870 million in fresh funding for growth.
HIMSPositive Net Change LFMDNegative Net Change TEMPositive Net Change
medical medical-devices
Doximity Stock Down Despite Q2 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
DOCS Q2 results benefit from the rise in AI-driven engagement. However, the stock plunges nearly 9% in pre-market trading.
BSXNegative Net Change WSTPositive Net Change EXASPositive Net Change DOCSPositive Net Change
earnings medical medical-devices
SOLV Gains on Q3 Earnings & Sales Beat, Raises '25 EPS Outlook
by Zacks Equity Research
Solventum posts strong Q3 results with a revenue and earnings beat, lifts 2025 EPS guidance on solid MedSurg and HIS growth.
BSXNegative Net Change MCKPositive Net Change ALCPositive Net Change SOLVPositive Net Change
earnings medical medical-devices
Hologic's Breast Health Rebounds, Takes Spotlight in Buyout Deal
by Moumi Mondal
After a strong Q4 rebound, HOLX's Breast Health takes center stage in the company's upcoming private equity takeover.
BDXPositive Net Change HOLXPositive Net Change GEHCPositive Net Change
medical medical-devices
QuidelOrtho Q3 Earnings and Revenues Beat Estimates, Margins Expand
by Zacks Equity Research
QDEL tops Q3 estimates as Labs and Immunohematology units drive growth, while margins strengthen despite respiratory revenue declines.
BSXNegative Net Change QDELPositive Net Change WSTPositive Net Change EXASPositive Net Change
earnings medical medical-devices
Inogen Stock Dips Despite Q3 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
INGN stock slid despite a narrower Q3 loss and rising B2B demand, as weaker consumer and rental sales weighed on results.
BSXNegative Net Change WSTPositive Net Change INGNNegative Net Change EXASPositive Net Change
earnings medical medical-devices
PACB Stock Down Despite Q3 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
PacBio posts a narrower Q3 loss and margin gains, but shares fall as revenues dip amid softer instrument demand.
BSXNegative Net Change WSTPositive Net Change PACBNegative Net Change EXASPositive Net Change
earnings medical medical-devices
CONMED Q3 Earnings and Revenues Beat Estimates, Margins Contract
by Zacks Equity Research
CNMD beats third-quarter 2025 estimates on strength in surgery segments, but gross and operating margins see sharp contraction.
BSXNegative Net Change CNMDNegative Net Change WSTPositive Net Change EXASPositive Net Change
earnings medical medical-devices
BD Stock Slips in Pre-Market Despite Q4 Earnings Beat, Margins Up
by Zacks Equity Research
BDX tops fourth-quarter fiscal 2025 earnings estimates and posts strong margin gains, with growth across all business segments and geographies.
BSXNegative Net Change BDXPositive Net Change WSTPositive Net Change EXASPositive Net Change
earnings medical medical-devices